A Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic Amyloidosis
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs GSK 2315698 (Primary) ; GSK 2398852 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 09 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.